Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
This article was originally published in The Rose Sheet
Executive Summary
Jan Marini Skin Research (JMSR) is suspending sales of its two Age Intervention eyelash products in the U.S. - citing an uncertain regulatory environment and the daunting prospect of litigation - and focusing on its core skin-care line and opportunities abroad
You may also be interested in...
CIR Expert Panel’s Prostaglandin Review: Uncertainties Persist Around ‘Eye Makeup’ Ingredients
Cosmetic Ingredient Review’s expert panel issued an insufficient data announcement for two prostaglandin analogs at its June meeting in Washington. The group is reviewing the substances – related to the active ingredient in Allergan’s prescription drug Latisse for eyelash growth – after the US FDA indicated that they could be used lawfully in cosmetic products.
Jan Marini Delves Into Men's Skin Care With Five-Product System
To make it easier for men to "measurably improve" their skin conditions, Jan Marini Skin Research launches a five-step regimen for long-term daily use
Jan Marini Delves Into Men's Skin Care With Five-Product System
To make it easier for men to "measurably improve" their skin conditions, Jan Marini Skin Research launches a five-step regimen for long-term daily use